Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies.
about
Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.Hizentra for the treatment of primary immunodeficiency.Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.Non-AUG start codons responsible for ABO weak blood group alleles on initiation mutant backgrounds.
P2860
Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prion removal capacity of plas ...... on from PPTA member companies.
@ast
Prion removal capacity of plas ...... on from PPTA member companies.
@en
type
label
Prion removal capacity of plas ...... on from PPTA member companies.
@ast
Prion removal capacity of plas ...... on from PPTA member companies.
@en
prefLabel
Prion removal capacity of plas ...... on from PPTA member companies.
@ast
Prion removal capacity of plas ...... on from PPTA member companies.
@en
P2093
P2860
P356
P1433
P1476
Prion removal capacity of plas ...... on from PPTA member companies.
@en
P2093
Albrecht Gröner
Christoph Kempf
Douglas C Lee
Eckhard Flechsig
Fabrizio Fabbrizzi
Gerhard Pölsler
Herbert O Dichtelmüller
Ilka von Hoegen
Juan I Jorquera
P2860
P304
P356
10.1111/TRF.12050
P577
2012-12-17T00:00:00Z